NCT04451239

Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis

Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Ameera Gamal Abdelhameed · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.

Detailed description

COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily . Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.

Conditions

• Keratonjunctivitis

Interventions

Type	Name	Description
DRUG	topical steroids and cyclosporin-A	All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .

Timeline

• Start date: 2020-06-30
• Primary completion: 2020-07-01
• Completion: 2020-07-01
• First posted: 2020-06-30
• Last updated: 2020-06-30

Locations

1 site across 1 country: Kuwait